BioCentury | Feb 13, 2020
Product Development

COVID-19 update: Remdesivir readout in weeks; hospital-use diagnostic under development; antibodies advancing

Initial signals from two ongoing trials in China of Gilead’s remdesivir to treat COVID-19 should be available in a few weeks, Marie-Paule Kieny said at a WHO press conference Wednesday. Assistant Director-General Kieny co-chaired the...
BioCentury | Feb 8, 2020
Product Development

Feb. 7 Product Development Quick Takes: Myriad tumbles on revenue miss; plus Verana, Sanofi, VIB, Coda, Blueprint

Myriad misses Street as CEO Capone departs Myriad Genetics Inc. (NASDAQ:MYGN) fell $8.27 (28%) to $21.02 after reporting fiscal 2Q20 EPS and revenues that missed consensus estimates and announcing the departure of President and CEO...
BioCentury | Feb 5, 2020
Product Development

2019-nCoV drug discovery: HHS funds Regeneron mAbs and BenevolentAI deploys machine learning

Regeneron and BenevolentAI unveiled a deal and a platform, respectively, on Tuesday that could yield therapies against 2019-nCoV that go beyond anti-inflammatory drugs for other viral infections. The first nine clinical trials of medicines for...
BC Week In Review | Jan 2, 2012
Clinical News

GSK2586881: Phase IIa started

GlaxoSmithKline began a U.S. and Canadian Phase IIa trial to evaluate GSK2586881 in ALS patients. GSK has exclusive, worldwide rights to develop and commercialize the compound from Apeiron (see BioCentury, Feb. 8, 2010). Apeiron Biologics...
BioCentury | Feb 28, 2011
Product Development

Two for one in neuroblastoma

By activating multiple elements of the host's immune system, Apeiron Biologics AG believes its mAb fused to IL-2 will provide a one-two punch to neuroblastoma cells, without the toxic side effects of systemic IL-2 treatment....
BC Innovations | Sep 2, 2010
Distillery Therapeutics

Indication: Cardiovascular disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Atherosclerosis Angiotensin I converting enzyme 2 (ACE2) In vitro studies suggest that increasing ACE2 levels could help treat atherosclerosis. In aortic segments from atherosclerotic...
BC Week In Review | Feb 8, 2010
Company News

Apeiron Biologics, GlaxoSmithKline deal

Apeiron granted GlaxoSmithKline exclusive, worldwide rights to develop and commercialize APN01 . The recombinant human angiotensin-converting enzyme 2 (ACE2) is in Phase I testing to treat acute respiratory distress syndrome (ARDS). Apeiron will receive £11 million...
BC Extra | Feb 4, 2010
Company News

GSK in-licenses Apeiron's APN01

Apeiron Biologics AG (Vienna, Austria) granted GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) exclusive, worldwide rights to APN01. The recombinant human angiotensin-converting enzyme 2 (ACE2) is in Phase I testing to treat acute respiratory distress syndrome. Apeiron will...
BC Week In Review | Dec 22, 2008
Clinical News

GL1001: Phase I data

Data from a 14-day, double-blind, placebo-controlled, ascending-dose, U.S. Phase I trial in 32 healthy volunteers showed that multiple doses up to 1,800 mg oral GL1001 were well tolerated with no serious adverse events. Ore Pharmaceuticals...
BC Week In Review | Oct 6, 2008
Clinical News

GL1001: Phase I started

Ore began a double-blind, placebo-controlled, multiple ascending-dose, U.S. Phase I trial to evaluate oral GL1001 in up to 30 healthy volunteers. Ore Pharmaceuticals Inc. (NASDAQ:ORXE), Gaithersburg, Md.   Product: GL1001   Business: Autoimmune   Molecular...
Items per page:
1 - 10 of 20